| Description |
| Product Type |
Product Size |
| Injection |
1'S |
| Product Company |
| Roche Pharma |
Pertuzumab 420mg/14ml |
| Product Type |
Product Size |
| Tablet |
30'S |
| Product Company |
| Martin Dow |
Anastrozole 1mg |
| Product Type |
Product Size |
| Injection
|
1'S |
| Product Company |
| Helix pharma
|
Doxorubicin 50mg/25ml
|
| Product Type |
Product Size |
| Tablet |
30'S |
| Product Company |
| Manufacture Deva Holding / Marketed by Searle |
Letrozole 2.5mg |
| Product Type |
Product Size |
| Injection |
1'S |
| Product Company |
| Roche Pharma |
Bevacizumab 400mg/16ml |
| Product Type |
Product Size |
Product Company |
| Injection |
1'S |
Pharmasol |
|
| Content | "
Pertuzumab is a monoclonal antibody. . Monoclonal antibodies work by attaching to proteins on or in cancer cells. Human epidermal growth factor 2 (HER2) is a protein that makes cells grow and divide. | Anastrozole is a type of hormone treatment. It works by lowering the levels of oestrogen hormones in your body. It is mainly prescribed for women who have been through the menopause and have a type of cancer called hormone-dependent breast cancer. | Doxorubicin is a type of chemotherapy drug called an anthracycline. It slows or stops the growth of cancer cells by blocking an enzyme called topo isomerase 2. Cancer cells need this enzyme to divide and grow.
| Letrozole is a non-steroidal type II aromatase inhibitor. It blocks the active site, and therefore the electron transfer chain of CYP19A1. This competitive inhibition prevents the conversion of androgens to estrogen. This action leads to a reduction in uterine weight and elevated leuteinizing hormon. | "
Bevacizumab is a type of targeted cancer drug treatment. It is also known as Avastin. It is a treatment for a number of different cancer types. | Vincristine is a chemotherapy drug that belongs to a group of drugs called vinca alkaloids. Vincristine works by stopping the cancer cells from separating into 2 new cells. So, it stops the growth of the cancer. |
Reviews
There are no reviews yet.